RCT: High dose once a week Semaglutide (2.4 mg) in adults with overweight or obesity, and type 2 diabetes

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial – The Lancet

Commentary: Drug found effective for weight loss in patients with obesity and diabetes, international study show – UT Southwestern Medical Center